Navigation Links
Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)
Date:10/10/2008

SWARTZ CREEK, Mich., Oct. 10 /PRNewswire/ -- Diplomat Specialty Pharmacy announced today that Teva Neuroscience has selected Diplomat Specialty Pharmacy to be one of only three sites to participate in a large scale, national Therapy Optimization Study for Multiple Sclerosis (TOP MS).

The goal, of the two year TOP MS study, is to examine the benefits of a specialty pharmacy therapy management program on compliance, adherence and patient outcomes. Targeted patient outcomes will include: Relapses, Disability Progression, Quality of Life, and Work and Usual Activity Participation.

"We are honored that Teva Neuroscience selected Diplomat to participate in this study," said Phil Hagerman, President and CEO of Diplomat. "I have no doubt that the TOP MS study will validate the benefits of our patient centric model. When we focus on adherence and tolerance, and offer patients a personalized medication program, we can reduce the frequency and severity of relapses and ultimately improve the quality of life."

"Diplomat Specialty Pharmacy was selected to participate in this study because they have shown a commitment to therapy management in MS that is exemplary among Specialty Pharmacies," said MerriKay Oleen-Burkey, Project Leader for the TOP MS Study at Teva Neuroscience.

"This really is a credit to Diplomat's industry leading MS Navigator program that currently benefits physicians and especially MS patients across the country," said Ken Visser, Diplomat's National Accounts Manager for Multiple Sclerosis. "At Diplomat we maximize therapy adherence by enhancing patient education and prescriber communication. Using our exclusive eNAV(TM) patient care software system, we can electronically record and report our patients' therapy and disease. All of this combined amounts to some of the highest patient adherence numbers in the country."

About Diplomat Specialty Pharmacy

Diplomat Specialty Pharmacy is the nation's largest independently held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Crohn's and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio-Identical Hormone Replacement Therapy and Specialty Compounding. The company also specializes in Disease Management programs for Chronic Kidney Disease patients, as well as Home and Out-Patient Infusion. With locations in Flint, Swartz Creek and Grand Rapids, MI; Cleveland, OH; Chicago, IL; and Ft. Lauderdale, Florida; Diplomat services the specialty pharmacy needs of patients and physicians nationwide.

About Teva Neuroscience

Teva Neuroscience is the branded neurological products franchise of Teva Pharmaceutical Industries Ltd. and is responsible for the development, registration and marketing for Teva's branded neurological products in North America. Teva Neuroscience has administrative, commercial marketing, and other leadership functions based in Kansas City, MO at its North American headquarters, as well as a facility in Horsham, PA, home to the company's clinical research activities and regulatory functions, and an office in Montreal, Quebec, headquarters for the company's Canadian presence.

Contact: Ken Visser, National Accounts Manager for Multiple Sclerosis

Phone: 616-242-1082

Fax: 616-454-9095

Email: kvisser@diplomatpharmacy.com


'/>"/>
SOURCE Diplomat Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
2. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
3. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
4. U.S. Preventive Medicine Acquires Specialty Disease Management
5. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
6. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
7. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
8. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
9. RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION
10. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
11. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , February 20, 2017 According to a new ... Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, ... by MarketsandMarkets, The market is projected to reach USD 52.37 Billion by ... during the forecast period. Continue Reading ... ...
(Date:2/20/2017)...   Alberty   Drugs , a ... has announced a significant shift in focus by ... to servicing local Veteran Affairs Centers (VA) and other ... increased need to secure cost effective treatments for their ... for their goods & services. "The opportunity ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... ... Smiles by Seese is a comprehensive family dental practice located ... practice as a skilled and highly credentialed dentist who is qualified to perform a ... all ages with excellence in general, restorative, and cosmetic dentistry . Their services ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... on foundational and sustainable systems change designed to further positively impact the health ... Board of Trustees has long considered it our duty to seriously consider releasing ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Carol Francis' goals for each and every seminar, session and class she ... demonstrate five different brainwave tools which help energize creativity, focus mental functions, enhance ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum Awards ... healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, highlighting ...
Breaking Medicine News(10 mins):